Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol
Biotech
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
The patient who had two grade 3 side effects after receiving VERVE-101 was asymptotic, and lab abnormalities resolved within days.
Max Bayer
Apr 2, 2024 7:00am
Epigenetic silencing lasts in mice, Chroma-sponsored study shows
Feb 28, 2024 11:00am
FDA frees Verve's base editing therapy from clinical hold
Oct 23, 2023 6:30am
LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial
Aug 29, 2023 6:30am
AstraZeneca returns to hypercholesterolemia via Chinese R&D pact
Jun 16, 2023 9:27am
FDA hands Verve list of demands for lifting gene editing hold
Dec 5, 2022 9:20am